Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akorn Gets First Lyo-Product Approval for Decatur Site | Contract Pharma

What are you searching for?

Sign in
Breaking News

Akorn Gets First Lyo-Product Approval for Decatur Site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has granted supplemental NDA approval for Akorn, Inc.’s IC-Green for Injection, USP. This approval is Akorn’s first lyophilized product approval for manufacture in its Decatur, IL production facility.
   
The company has invested approximately $23 million in a new liquid and lyophilized injectable manufacturing fill line at its Decatur facility. In December 2007, the company announced successful results of an FDA pre-approval inspection (PAI) for lyophilized products.
   
Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “We are very excited to announce the FDA approval of our first Akorn-manufactured lyophilized injectable product. We intend to commercialize our lyophilization manufacturing capabilities by developing an internal ANDA injectable product line and by expanding our contract pharmaceutical manufacturing business segment to include lyophilized injectable products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics